Patient Involvement in HTA

Principles of Patient Involvement in HTA

The National Centre for Pharmacoeconomics is committed to facilitating the involvement of patients in the Health Technology Assessment (HTA) process. We believe that patients have perspectives and experiences that can uniquely contribute to the decision making process. We also consider that patients should have the same rights to contribute to HTA as other stakeholders, and this requires processes to enable effective engagement. With this in mind, the NCPE provide the Patient Organisation Submission process, to enable patient groups to communicate their experiences directly to the decision maker, the Health Services Executive (HSE).

The Patient Organisation Submission Process encourages Patient Organisations to gather information from their members for inclusion in the Patient Organisation Submission of Evidence Template. In particular, this template includes information on the day-to-day experience of living with the disease and the ways in which the new drug may improve this day-to-day experience. This information can help the HSE Drugs Committee to understand the real-world impact a new drug may have on the quality of life and daily experience of patients and carers.

Figure 1 Information provided in NCPE HTA report to the HSE Drugs Committee

Process Overview

The NCPE have identified three key steps in the Patient Submission Process; Identification and Notification of the Patient Organisation, Submission of Patient Organisation Submission of Evidence Template, and Notification of outcome by NCPE (Figure 2).

Figure 2 NCPE Patient Organisation Submission Process overview



1. Identification and Invitation process

Patient Organisations are invited to join the NCPE Patient Organisation Database, and consent to being contacted by the NCPE if HTAs in their therapeutic area of interest are commissioned by the HSE. To register, patient organisations must complete the Registration Form. They will then be contacted directly by the NCPE and invited to put together a Patient Submission of Evidence Template, if a relevant new drug is commissioned for HTA by the HSE.

2. Submission process

Detailed guidance on the submission process is provided on the NCPE website, including a step by step guide to completing the Submission of Evidence Template. The NCPE include the Patient Organisation Submission of Evidence Template in its entirety in an Appendix of our final report to the HSE, and also include extracts of the Template within the main body of the report.

3. Notification process

The NCPE will notify the submitting Patient Organisation of the outcome of the HTA report 48 hours prior to the publication of the summary report on the NCPE website.